abstract Exon-specific anti-dystrophin antibodies are used to monitor the success of treatments for Duchenne muscular dystrophy that aim to restore the missing dystrophin protein. Dystrophin is a large cytoskeletal protein encoded by 79 exons and expressed mainly in muscle. Most cases of Duchenne and Becker muscular dystrophies are caused by genetic deletion of one or more exons. In-frame deletions permit some synthesis of internally-deleted dystrophin and cause the milder Becker form, while out-of-frame deletions in the severe Duchenne form result in early stop-codons and no functional dystrophin synthesis. In this study, we describe the production of ten new monoclonal antibodies against a rod region encoded by exons 55-59 and their mapping to specific dystrophin exons, thus filling a major gap in the spectrum of available antibodies. The antibodies have already been applied in a published clinical trial of a drug treatment for Duchenne muscular dystrophy.
introduction
The aim of this study, which has been in progress for over ten years, has been to produce monoclonal antibodies (mAbs) that recognise specific amino-acid sequences spread throughout the dystrophin molecule (3, 684 amino-acids). The 150 mAbs that we have produced so far recognise sequences encoded by 34 of the 79 exons of dystrophin, ranging from exon 1 to exon 77. We have paid particular attention to the exons that are commonly deleted in Duchenne muscular dystrophy and have shown that they can be used to characterise mutant Becker dystrophins at the protein level in muscle biopsies [1] . The antibodies have been used to characterise the various short forms of dystrophin, Dp71 [2] [3] [4] , Dp116, Dp140 [5] and Dp260 [6] , and were often used in the first descriptions of these short forms. One of the most important applications of the mAbs has been in the characterisation of revertant fibres in Duchenne patients [7] and mdx mice [8] . The dystrophin in revertant fibres always has missing exons (in-frame deletions) whereas dystrophin supplied in gene or cell therapy trials is usually full-length. Since some early apparent successes with cell therapy were shown to be mistakenly due to revertant fibres [9] 
Hybridoma production
We have described the method in great detail elsewhere [11] . All monoclonal antibodies produced in the present study were of the IgG1 subtype.
Western blotting SDS-PAGE on 15% polyacrylamide gels and
Western blotting on nitrocellulose membranes were carried out essentially as described elsewhere [12] . Antibody reacting bands were visualized following development with The mAbs were mapped using PCRgenerated subfragments also expressed in On western blots, all ten mAbs detected a dystrophin band at 427kD in SDS extracts of human skeletal muscle (Figure 3) . Many of the lower Mr bands were recognised by nearly all of the mAbs, suggesting that they may be degradation products of dystrophin which lack the N-terminus. We have shown elsewhere that dystrophin in vivo is degraded progressively from its N-terminus [13] . However, the possibility that one of the minor bands might be Dp116 has not been ruled out. These results are summarized in Table 2 .
discussion
Several different approaches have been used in the attempt to replace the missing dystrophin protein in Duchenne muscle. Attempts have been made to introduce normal muscle-cell precursors into Duchenne muscle (myoblast cell therapy) [14] . Bone-marrow-derived stem cell transplantation can also give rise to dystrophin-positive fibres in Duchenne muscle [10] . Viral vectors or DNA alone have been used to introduce normal dystrophin-encoding DNA permanently into muscle cells (gene therapy) [15] . Drugs that cause "read-through" of nonsense mutations may be effective in those few cases with this type of mutation [16] .
Oligonucleotide-based drugs have been used to cause targeted exon-skipping that restores the reading-frame when the dystrophin mRNA is produced from the primary RNA transcript [17] . Many of these approaches have potential problems with effective delivery and with the immune response (against cells, DNA and even dystrophin itself ) [18] . In some, the aim is to "convert" the Duchenne phenotype into a Becker, rather than to affect a complete cure. Table 1 . Epitope mapping using PCR-generated sub-fragments.
The theoretical patterns of binding to sub-fragments used in Figure 1 are shown and they match the actual binding patterns for 3 groups of mAb. A total protein extract of human skeletal muscle was separated on a 3-15% acrylamide gradient gel, transferred to nitrocellulose and cut into strips for reaction with different mAbs. The position of the dystrophin band at 427kD was identified using an established mAb against dystrophin (MANDYS1, not shown). 
